Levodopa/Carbidopa/Entacapon Ratiopharm (Carbidopa, Entacapone, Levodopa)

Levodopa/Carbidopa/Entacapon is used in Parkinson's disease therapy to enhance dopaminergic treatment and manage motor fluctuations.

• Parkinson's disease (early stage): improves bradykinesia, rigidity and tremor.
• Parkinson's disease with motor fluctuations: reduces "off" periods and prolongs levodopa effect.
• Advanced Parkinson's disease: provides more consistent dopaminergic stimulation for overall motor control.
• Parkinson's disease patients on levodopa monotherapy: serves as an adjunct to improve symptom control.
• Parkinson's disease with dyskinesia: helps balance levodopa dosing to minimize involuntary movements.

• The combination delivers levodopa, a dopamine precursor that crosses the blood‑brain barrier and is converted to dopamine in the central nervous system. Carbidopa inhibits peripheral aromatic L‑amino‑acid decarboxylase, preventing premature conversion of levodopa and increasing its cerebral availability. Entacapone blocks catechol‑O‑methyltransferase (COMT), reducing peripheral levodopa metabolism and extending its plasma half‑life, thereby providing a more stable and overall significant dopaminergic effect.

Levodopa/Carbidopa/Entacapon may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects

• Nausea: gastrointestinal upset often occurring at treatment initiation.
• Dizziness: light‑headedness, especially when standing quickly.
• Orthostatic hypotension: drop in blood pressure upon standing.
• Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects

• Severe hypotension: marked blood pressure decline requiring medical attention.
• Hallucinations or psychosis: visual disturbances or altered perception.
• Dyskinesia: involuntary, erratic movements that may affect daily activities.

When prescribing Levodopa/Carbidopa/Entacapon, clinicians should observe several safety measures.

• Blood pressure monitoring: check for orthostatic hypotension regularly.
• Psychiatric assessment: evaluate for hallucinations or mood changes before and during therapy.
• Liver function testing: monitor hepatic enzymes due to metabolism involvement.
• Renal impairment adjustment: consider dose modification in patients with reduced kidney function.
• Concomitant MAO‑B inhibitors: avoid use together to prevent hypertensive crisis.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and light.

Levodopa/Carbidopa/Entacapon interacts with several drug classes; awareness of these interactions helps prevent adverse events.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors: risk of hypertensive crisis.
• Antipsychotic drugs (dopamine antagonists): may diminish therapeutic effect.
• Certain antihypertensives (alpha‑blockers): can exacerbate orthostatic hypotension.

Moderate Interactions (Monitor Closely)

• SSRIs or SNRIs: may increase risk of serotonin syndrome.
• Iron or calcium supplements: can reduce levodopa absorption if taken simultaneously.